CJC-1295 (no-DAC / Modified GRF 1-29)
Mod GRF 1-29, Modified GRF (1-29), CJC-1295 without DAC, tetrasubstituted GRF(1-29), "CJC-1295 DAC-less"
The Ground Truth Score
four plain questions, never one numberNo human trial of its own; rides on a cousin's data
Bottom line
A short-acting GHRH analog with a sound mechanism and a sister molecule (CJC-1295 DAC) that has real human data, but the no-DAC version itself has never completed a published controlled human trial, it is animal-grade evidence dressed in its cousin's credibility.
Does the science back it?
Do real people feel it?
Is it safe?
Could it be placebo?
"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.
Why is the evidence this thin? It's mostly economics →
Dose at a glance
full dosing ↓Reported (not prescribed) research/clinic dosing: ~100 mcg per injection as a common starting point, titrated up by ~50 mcg every 1-2 weeks toward roughly 100-300 mcg per dose, given 1-3x/day.
Reported, not prescribed. Verify your vial and your math.
First documented human use
No controlled human trial of the no-DAC compound (Modified GRF 1-29) has been completed or published. The molecule was first characterized as a "long-lasting GRF analog" in research around 2005. The widely cited human RCT (Teichman et al., JCEM 2006) studied CJC-1295 WITH DAC, a structurally different long-acting molecule, not this one. Human exposure to the no-DAC version is essentially limited to off-label clinic use and self-experimentation in the gray market from roughly the early-2010s onward; none of it is documented in controlled trials.
The pitch
What people claim it does
Stated plainly and neutrally, exactly as you'll hear it. I grade each one below.
- A truncated, enzyme-resistant analog of growth-hormone-releasing hormone (GHRH) that prompts the pituitary to release its own GH in a natural pulse.
- Four amino-acid substitutions (positions 2, 8, 15, 27) extend its half-life from under ~10 minutes (native GRF) to roughly 30 minutes, long enough to drive one meaningful GH pulse.
- Almost always stacked with a GHRP/ghrelin-mimetic such as ipamorelin for a claimed synergistic GH release.
- Marketed for lean-mass support, fat loss, recovery and sleep quality, all downstream of raising GH/IGF-1.
- Preferred over the DAC version by users who want pulsatile, short-lived GH elevation rather than a continuous multi-day 'bleed' of GH.
The data behind each bullet
What actually backs it
The no-DAC compound (Modified GRF 1-29) itself has no completed, published controlled human trial; its human-relevant evidence is extrapolated from the DAC version and from rat data.
Literature searches surface no RCT, pilot, or observational study of the no-DAC molecule specifically. The encyclopedic record and review sources describe it via rat pharmacokinetics and by analogy to CJC-1295 DAC. Absence of a human trial is itself the key finding.
PubMed search: modified GRF (1-29) / CJC-1295 without DAC ↗The frequently cited 'CJC-1295 raises GH 2-10x and IGF-1 1.5-3x for several days in healthy adults' result is from the DAC version, not the no-DAC version.
Teichman et al., randomized placebo-controlled double-blind ascending-dose trials in healthy adults, JCEM 2006, but the agent was CJC-1295 WITH DAC (albumin-binding, ~6-8 day half-life). This human RCT does not validate the short-acting no-DAC molecule.
Teichman et al., JCEM 2006 (PMID 16352683). CJC-1295 DAC ↗GHRH-analog stimulation of GH/IGF-1 is a real, dose-dependent biological mechanism in humans (class-level), supporting biological plausibility even where this exact molecule is untested.
The GHRH-receptor → pituitary GH → hepatic IGF-1 axis is well established; the approved GHRH analog sermorelin (Geref) and the DAC trial demonstrate the pathway works in humans. Plausibility is high; molecule-specific human efficacy is not established.
PubMed search: GHRH analog growth hormone secretion humans ↗No CJC-1295 product (DAC or no-DAC) is FDA-approved; it has no USP/NF monograph and sits in a regulatory gray zone after being dropped from the FDA 503A interim bulks list.
FDA removed CJC-1295 from Category 2 of the interim 503A bulks list in 2024 after the nominator withdrew it; it was not moved to Category 1 (permitted for compounding). It remains neither approved nor a recognized compounding substance. This is a regulatory fact, graded A for the fact itself.
FDA. 503A bulk drug substances / PCAC compounding pages ↗Development of CJC-1295 (DAC) was halted in phase II after a trial subject died; the death was attributed by the attending physician to pre-existing coronary artery disease and judged unrelated, but the program stopped.
Reported in the encyclopedic record of CJC-1295's development history. Causality was adjudicated as unrelated (pre-existing CAD), but the event ended clinical development and is material context for the safety lens.
ClinicalTrials.gov search: CJC-1295 ↗In rodents, modified/tetrasubstituted GRF(1-29) shows greater GH-releasing potency and AUC than unmodified GRF(1-29) due to enzymatic stability, but this is animal, not human, efficacy.
Rat pharmacology described in review/secondary literature (related analogs ~4-fold greater 2-hour GH AUC vs unmodified GRF). Animal data does not raise the human evidence grade.
PubMed search: GRF 1-29 analog rat growth hormone potency ↗Mechanism
How it's assumed to work
Assumed · theoretical pathway
Assumed mechanism (class-validated, molecule-specific human data absent): Modified GRF 1-29 is a truncated, enzyme-stabilized analog of growth-hormone-releasing hormone (GHRH). It is assumed to bind the pituitary GHRH receptor on somatotrophs and stimulate synthesis and pulsatile release of the body's own growth hormone, which in turn raises hepatic IGF-1. The four amino-acid substitutions are assumed to slow degradation by DPP-IV and other peptidases, lengthening the active window to ~30 minutes, enough to drive a single GH pulse. Because it acts upstream through the pituitary (rather than being injected GH), the resulting GH rise is assumed to remain under normal somatostatin negative feedback, preserving pulsatility; this is the theoretical safety argument but is unproven for this molecule in humans.
Dosing & handling
What users and clinicians report
Reported (not prescribed) research/clinic dosing: ~100 mcg per injection as a common starting point, titrated up by ~50 mcg every 1-2 weeks toward roughly 100-300 mcg per dose, given 1-3x/day. A frequent pattern is 100 mcg once daily pre-bed, or 100 mcg up to 2-3x/day timed to natural GH-pulse windows (pre-bed, post-workout, and/or upon waking). Almost always co-administered with ~100-300 mcg ipamorelin in the same syringe. The '100 mcg' figure is tied to a 'saturation dose' folklore concept (the dose said to maximally stimulate the pituitary per pulse) rather than to any human dose-finding trial.
All dosing above is community/clinic convention, not established by any controlled human trial of this compound, and the '100 mcg saturation dose' is heuristic, not validated. Gray-market vials vary in true peptide content, purity and fill accuracy, so the actual delivered dose is uncertain regardless of the label. There is no validated therapeutic window for the no-DAC molecule in humans. Do not infer safety of any total daily amount from these reported numbers.
Timing & food
Reportedly dosed subcutaneously in a fasted/low-insulin window, typically pre-bed and/or fasted upon waking and/or post-workout. The food rule matters: a carbohydrate/fat-containing meal raises insulin and somatostatin, which blunts the GH pulse, so users are advised to inject at least ~2-3 hours after eating and to wait ~20-30 minutes before the next meal. Pre-bed dosing is favored to ride the largest natural nocturnal GH pulse and is also why drowsiness is a common reported effect. All timing logic is mechanism-based convention, not trial-derived.
Half-life
Approximately 30 minutes (vs under ~10 minutes for native GRF 1-29/sermorelin). This is the defining contrast with CJC-1295 WITH DAC, whose albumin-binding lysine-maleimide complex extends its half-life to roughly 6-8 days. The short half-life is why no-DAC dosing is frequent (1-3x/day) and timed to GH-pulse windows.
Reconstitution sensitivity
Supplied as a lyophilized powder, reasonably stable at room temperature while sealed and dry; should be kept away from light, heat and moisture. Reconstitute gently with bacteriostatic water (aim the stream down the vial wall, do not shake, swirl), as peptide chains are shear- and heat-sensitive. After reconstitution, refrigerate at 2-8 C, protect from light, and avoid repeated warming/cooling (temperature cycling) and freezing of the reconstituted solution; reconstituted product is commonly cited as usable for roughly up to ~30 days. Degraded/cloudy or discolored solution should be discarded. Sloppy handling is a real source of lost potency and is often mistaken for a 'non-responder' outcome.
Real-world signal
What people actually report
Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.
Volume
High chatter volume. CJC-1295 (typically the no-DAC + ipamorelin combo) is one of the most widely discussed 'GH peptide' stacks across bodybuilding forums, peptide communities, anti-aging clinics and biohacking content, far more discussion than data. However, the volume is inflated by the ubiquity of vendor and clinic content and by the fact that reports almost never isolate the no-DAC molecule from its ipamorelin partner.
Consistency
Moderately consistent on the basics: users commonly report better/deeper sleep, improved recovery and a gradual recomposition (slightly leaner, fuller muscle) over weeks-to-months, plus the recognizable side-effect cluster (water retention, hand tingling, head-rush, hunger). Consistency drops on magnitude, claims range from 'subtle, mostly sleep' to dramatic, with the dramatic accounts heavily confounded by concurrent TRT, diet and other compounds. The side-effect pattern is more reliably reported than the benefit.
Source credibility
Low-to-moderate source credibility. A large share of available content is vendor or clinic marketing with an obvious commercial interest, which is discounted. The more credible signal comes from independent forum users describing both upsides and downsides, but these are uncontrolled, unverified-product, polypharmacy anecdotes. Net: enough believable real-world reporting to register as Moderate, but nothing here approaches proof, and the science behind it remains animal-grade.
- (Anecdote, not proof) The most consistent report is improved sleep depth and recovery within the first couple of weeks, especially with pre-bed dosing, though this is exactly where placebo/expectancy and the calming injection ritual are strongest.
- (Anecdote) Body-composition change is described as gradual and subtle over 8-12+ weeks (a bit leaner, fuller muscles) rather than dramatic, and is almost always reported alongside an ipamorelin stack, training and diet, so attribution to this peptide alone is weak.
- (Anecdote) The side-effect cluster is reported reliably: transient water retention/puffiness, tingling or numb fingers (carpal-tunnel-like), a warm flush or light-headed 'head-rush' shortly after injection, and increased hunger, usually described as mild and fading after the first weeks.
- (Anecdote) A recurring community theme is variability and skepticism: some users feel little to nothing, suspect under-dosed or degraded gray-market product, and debate the '100 mcg saturation dose' and fasted-timing rules as folklore, reflecting how much of the practice rests on convention rather than data.
Placebo risk, Moderate
Moderate, not High, because some claimed effects are at least partially objective/measurable: GH and IGF-1 can be assayed, and the GHRH mechanism is real, so a true physiologic effect is plausible. But the headline user-facing benefits people actually chase, 'better sleep,' 'faster recovery,' 'feeling leaner,' 'more well-being', are largely subjective, dose at bedtime (sleep expectancy), and ride on an injection ritual and a stacked regimen, all of which inflate placebo/expectancy. Without objective IGF-1 tracking, an individual cannot distinguish drug effect from expectation.
Risk panel
What could go wrong
Adverse events
Most commonly reported (anecdotal/clinic-level, not from controlled no-DAC trials): injection-site reactions (redness, itching, welts), transient water retention/puffiness, and paresthesia, tingling/numbness in hands and fingers resembling mild carpal-tunnel, a recognized consequence of GH-induced fluid retention compressing the median nerve. Also reported: increased appetite, post-injection flushing/head-rush, lightheadedness, headache, and drowsiness (often dosed pre-bed). Effects generally described as mild and settling within the first weeks. None of this is quantified by a controlled human trial of the no-DAC compound.
Theoretical concerns
Mechanistically, anything that chronically raises GH/IGF-1 carries the theoretical GH-excess risk set: insulin resistance / impaired glucose tolerance, fluid retention and carpal-tunnel-type symptoms, arthralgia, and, with sustained supraphysiologic elevation, a theoretical concern about promoting growth of existing neoplasia (IGF-1 is mitogenic). Because GHRH analogs work through the pituitary, the GH rise is theoretically self-limited by somatostatin feedback (unlike injected rHGH), which is the main argument for a wider margin, but that protective ceiling has not been characterized for this molecule in humans.
Contraindications
Should be avoided by anyone with active or recent malignancy (IGF-1 is mitogenic), and used with great caution in diabetes/insulin resistance (GH is diabetogenic). Caution with proliferative diabetic retinopathy and significant cardiovascular disease. Not for pregnancy/breastfeeding or in children/adolescents (open growth plates). The documented phase-II program death in a subject with pre-existing coronary artery disease (DAC version) underscores caution in established cardiac disease, even though that death was adjudicated unrelated. Gray-market product also carries contamination/mislabeling/dose-accuracy risk independent of the molecule.
Honest unknowns
The single largest unknown is that there is no completed controlled human trial of the no-DAC molecule, so its actual human dose-response, magnitude and durability of GH/IGF-1 effect, and long-term safety are simply unmeasured. Unknowns include: real-world purity/identity of gray-market vials, chronic-use effects on glucose metabolism and IGF-1 over months-to-years, cancer-risk signal, and whether the assumed pulsatile-GH safety advantage over the DAC version holds in practice. Long-term human safety data: none.
Confound watch
Attribution is badly muddied because mod GRF 1-29 is almost never run alone. It is typically stacked with ipamorelin (or another GHRP), so any benefit is a combined GHRH+GHRP effect, not this peptide's. Many users also concurrently run testosterone/TRT, other peptides (BPC-157, tesamorelin), GLP-1 agonists, or are simultaneously dieting and training hard, all of which independently change body composition, recovery and sleep. Improved sleep and 'recovery' are especially confounded by the pre-bed dosing ritual and expectancy.
History
Discovery → first use → status
- 1982-1983Native GRF/GHRH (1-44 and 1-29 fragments) characterized; GRF(1-29) ('sermorelin') established as the minimal active sequence that stimulates pituitary GH.
- 1990sSermorelin (Geref) reaches the market as an FDA-approved GHRH analog for GH-deficiency diagnosis/treatment, establishing the human GHRH-analog pathway. (Later discontinued commercially.)
- ~2005Tetrasubstituted Modified GRF (1-29), the no-DAC molecule, characterized as a 'long-lasting GRF analog,' with substitutions at positions 2, 8, 15 and 27 to resist enzymatic degradation (half-life extended to ~30 min).
- 2006Teichman et al. publish the human RCT of CJC-1295 WITH DAC (the albumin-binding, multi-day variant) in JCEM, the data most often (mis)cited for the no-DAC version.
- Late 2000sCJC-1295 (DAC) clinical development for lipodystrophy/GH deficiency reaches phase II, then is discontinued after a trial subject's death (attributed to pre-existing coronary artery disease).
- ~2010s onwardNo-DAC mod GRF 1-29 proliferates in the gray-market 'research peptide' channel, typically paired with ipamorelin; no controlled human trials of the no-DAC molecule are conducted.
- 2024FDA removes CJC-1295 from Category 2 of the interim 503A bulks list after the nominator withdraws it; FDA does not add it to Category 1. Leaves it unapproved and outside permitted compounding.
Verification
The COA standard, applied
Verified that the human RCT evidence (Teichman, JCEM 2006, PMID 16352683) belongs to CJC-1295 WITH DAC and does not transfer to the no-DAC molecule. Confirmed via PubMed and encyclopedic sources that no controlled human trial of Modified GRF 1-29 itself appears in the literature. Confirmed the structural basis (substitutions at positions 2/8/15/27; ~30-min half-life vs <10 min native; DAC = albumin-binding lysine-maleimide giving the DAC version a ~6-8 day half-life). Confirmed the phase-II development-halt-after-death history and the 2024 FDA 503A bulks-list removal. Treated all vendor/affiliate pages (peptide sellers, clinic blogs) as non-evidentiary and used them only for community-sentiment and handling conventions, not efficacy claims.
The full verification standard →Sources
Where this comes from
- Teichman et al., JCEM 2006. CJC-1295 (DAC) human RCT (PMID 16352683) ↗· The pivotal human trial, but of the DAC version, NOT the no-DAC molecule. Most-cited and most-misapplied source for mod GRF 1-29.
- PubMed search. Modified GRF (1-29) / CJC-1295 without DAC ↗· Run this to see for yourself: no controlled human trial of the no-DAC compound surfaces. The empty result is the headline.
- PubMed search. GHRH analog GH secretion in healthy adults (class plausibility) ↗· Establishes that the GHRH-receptor mechanism raises GH/IGF-1 in humans at the class level (incl. sermorelin).
- PubMed search. GRF(1-29) analog GH potency in rats ↗· Animal pharmacology underpinning the no-DAC molecule; animal-grade only.
- ClinicalTrials.gov. CJC-1295 trial record search ↗· Context for the discontinued DAC development program (phase II halt after a subject death adjudicated as pre-existing CAD).
- FDA. Bulk Drug Substances for Compounding under 503A ↗· Regulatory status: CJC-1295 not approved, no USP/NF monograph; removed from interim 503A Category 2 in 2024, not added to Category 1.
- FDA. Certain Bulk Drug Substances That May Present Significant Safety Risks ↗· Background on the Category 2 'significant safety risk' designation that applied to compounded peptides like CJC-1295.
The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.